IRAK1 and nasopharyngeal carcinoma: Moreover, Liu et al. demonstrated that downregulation of IRAK1 reversed the paclitaxel-resistance in nasopharyngeal carcinoma, and combined treatment of pacritinib with paclitaxel improved antitumor effect [46].